CJA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kao, Y. J.
Right arrow Articles by Le, N. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kao, Y. J.
Right arrow Articles by Le, N. D.

Canadian Journal of Anesthesia, Vol 43, 1128-1133, Copyright © 1996 by Canadian Anesthesiologists' Society

ARTICLES

The reversal of profound mivacurium-induced neuromuscular blockade

YJ Kao and ND Le
Department of Anesthesiology, Texas Tech University Health Sciences Center, Lubbock, USA.

PURPOSE: Mivacurium is metabolized by plasma cholinesterase catalyzed ester hydrolysis. Acetylcholinesterase antagonists used in the reversal of muscle relaxation may also inhibit plasma cholinesterase and, therefore, delay the hydrolysis of mivacurium. The clinical interaction between acetylcholinesterase antagonists and mivacurium induced neuromuscular blockade was studied. METHOD: Intraoperative muscle relaxation was maintained with a mivacurium infusion to achieve a constant intense block (first twitch, T1, 2-3% of control). Patients were randomly divided into three groups. Patients in Group 1 received no anticholinesterase, in Group 2 neostigmine 0.07 mg.kg-1, and in Group 3 edrophonium 1 mg.kg-1. The times between termination of the mivacurium infusion (Group 1) or the administration of the anticholinesterase (Groups 2 and 3) to 25%, 50%, 75% and 95% T1 recovery, and to 50%, 70% and 90% recovery in the ratio, T4/T1 (TR) were recorded. RESULT: In the neostigmine Group, T1 recovery to 25%, 50% and 75% (2.32 +/- 1.41, 3.90 +/- 1.85 and 6.88 +/- 2.66 min) was accelerated compared with control (3.36 +/- 1.34, 5.78 +/- 2.22, and 8.58 +/- 3.60, and), but recovery to 95% (18.53 +/- 9.09 vs 13.29 +/- 5.24 min) was delayed. Also, TR recovery to 50%, 70%, and 90% was slower (14.47 +/- 8.73, 21.25 +/- 11.06 and 31.37 +/- 12.11 min vs 11.75 +/- 3.74, 13.78 +/- 4.39 and 17.86 +/- 6.44 min). However, all T1 and TR recovery times were decreased in the edrophonium group (0.88 +/- 0.51, 2.00 +/- 1.50, 4.97 +/- 2.96, and 9.35 +/- 5.24 min for T1 and 6.86 +/- 3.93, 9.05 +/- 4.51 and 12.24 +/- 6.66 min for TR). CONCLUSION: Neostigmine reversal of intense mivacurium neuromuscular block should be avoided, as this may result in prolongation of the block.


This article has been cited by other articles:


Home page
 Canadian J. AnesthesiaHome page
T. Suzuki, C. A. Lien, M. R. Belmont, J. Tjan, and J. J. Savarese
Edrophonium effectively antagonizes neuromuscular block at the laryngeal adductors induced by rapacuronium, rocuronium and cisatracurium, but not mivacurium: [L'edrophonium antagonise efficacement le blocage neuromusculaire des adducteurs larynges induit par le rapacuronium, le rocuronium et le cisatracurium, mais non par le mivacurium]
Can J Anesth, November 1, 2003; 50(9): 879 - 885.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the Canadian Anesthesiologists' Society.